(HealthDay News) — Patients with metastatic melanoma who have high serum levels of vascular endothelial growth factor (VEGF) before treatment with ipilimumab have worse survival than patients with lower VEGF levels, according to a study published in the February issue of Cancer Immunology Research.

Jianda Yuan, MD, PhD, from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues retrospectively analyzed serum levels of VEGF in 176 patients with metastatic melanoma before and after treatment with 3 or 10 mg/kg ipilimumab (which targets CTL antigen 4).

RELATED: Skin Cancer Resource Center

Continue Reading

Using 43 pg/mL as the cutoff pretreatment VEGF value, the researchers observed clinical benefit at 24 weeks in 41.1% of patients below the cutoff but only 23.2% of patients at or above the cutoff. Median overall survival at 24 weeks was significantly lower in patients with VEGF at or above the cutoff (6.6 vs. 12.9 months [similar results observed at both ipilimumab doses]; hazard ratio, 1.6). 

There was no association between changes in VEGF levels during treatment and clinical outcome.

RELATED: Ipilimumab Offers ‘Prolonged’ Survival to Patients with Metastatic Melanoma

“Serum VEGF may be a predictive biomarker for ipilimumab treatment and is worthy of prospective investigation with various forms of immunologic checkpoint blockade,” Yuan and colleagues concluded.

Several authors disclosed financial ties to Bristol-Myers Squibb, which manufactures ipilimumab.


  1. Yuan J, Zhou J, Dong Z, et al. Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2014;doi: 10.1158/2326-6066.CIR-13-0163.